Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:DSGN NASDAQ:IPA NASDAQ:IVVD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$19.32+0.8%$15.89$7.08▼$20.43$399.54M0.6291,572 shs71,361 shsDSGNDesign Therapeutics$6.62+2.0%$5.81$2.60▼$7.77$377.00M1.68144,556 shs236,375 shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.19$0.27▼$3.25$96.68M0.531.83 million shs1.97 million shsIVVDInvivyd$1.63-13.3%$1.07$0.35▼$2.74$349.49M0.577.65 million shs9.24 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+5.16%-0.83%+27.71%+21.48%+62.46%DSGNDesign Therapeutics-3.85%+2.20%+7.63%+65.56%+29.80%IPAImmunoPrecise Antibodies0.00%0.00%0.00%+15.11%+256.29%IVVDInvivyd+6.82%+32.39%+31.47%+175.46%+84.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$19.32+0.8%$15.89$7.08▼$20.43$399.54M0.6291,572 shs71,361 shsDSGNDesign Therapeutics$6.62+2.0%$5.81$2.60▼$7.77$377.00M1.68144,556 shs236,375 shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.19$0.27▼$3.25$96.68M0.531.83 million shs1.97 million shsIVVDInvivyd$1.63-13.3%$1.07$0.35▼$2.74$349.49M0.577.65 million shs9.24 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+5.16%-0.83%+27.71%+21.48%+62.46%DSGNDesign Therapeutics-3.85%+2.20%+7.63%+65.56%+29.80%IPAImmunoPrecise Antibodies0.00%0.00%0.00%+15.11%+256.29%IVVDInvivyd+6.82%+32.39%+31.47%+175.46%+84.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.33Sell$12.00-37.89% DownsideDSGNDesign Therapeutics 1.00SellN/AN/AIPAImmunoPrecise Antibodies 3.00Buy$4.0090.93% UpsideIVVDInvivyd 2.83Moderate Buy$5.14215.18% UpsideCurrent Analyst Ratings BreakdownLatest IPA, DSGN, IVVD, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AMRNAmarinWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025DSGNDesign TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IVVDInvivydWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.00 ➝ $2.0010/6/2025IVVDInvivydCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$10.009/27/2025AMRNAmarinWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DSGNDesign TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IVVDInvivydWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/27/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/25/2025AMRNAmarinZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/25/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $1.00(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.75N/AN/A$23.62 per share0.82DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/AIPAImmunoPrecise Antibodies$17.59M5.50N/AN/A$0.37 per share5.66IVVDInvivyd$25.38M13.77N/AN/A$0.56 per share2.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%10/29/2025 (Estimated)DSGNDesign Therapeutics-$49.59M-$1.12N/AN/AN/AN/A-27.15%-26.07%11/6/2025 (Estimated)IPAImmunoPrecise Antibodies-$21.69M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%12/10/2025 (Estimated)IVVDInvivyd-$169.93M-$0.92N/A14.82N/A-238.33%-177.89%-90.96%11/13/2025 (Estimated)Latest IPA, DSGN, IVVD, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025DSGNDesign Therapeutics-$0.34N/AN/AN/AN/AN/A10/29/2025Q3 2025AMRNAmarin$0.31N/AN/AN/A$42.04 millionN/A8/14/2025Q2 2025IVVDInvivyd-$0.04-$0.12-$0.08-$0.12$23.16 million$11.79 million8/7/2025Q1 2025DSGNDesign Therapeutics-$0.32-$0.34-$0.02-$0.34N/AN/A7/30/2025Q2 2025AMRNAmarin-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 million7/29/2025Q4 2025IPAImmunoPrecise Antibodies-$0.02-$0.04-$0.02-$0.04$7.89 million$5.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.262.34DSGNDesign TherapeuticsN/A25.1325.13IPAImmunoPrecise Antibodies0.492.081.85IVVDInvivydN/A1.331.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%DSGNDesign Therapeutics56.64%IPAImmunoPrecise Antibodies6.70%IVVDInvivyd70.36%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%DSGNDesign Therapeutics23.50%IPAImmunoPrecise Antibodies6.83%IVVDInvivyd25.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.68 million20.28 millionOptionableDSGNDesign Therapeutics4056.95 million43.57 millionOptionableIPAImmunoPrecise Antibodies8046.15 million43.00 millionNot OptionableIVVDInvivyd100214.41 million159.95 millionOptionableIPA, DSGN, IVVD, and AMRN HeadlinesRecent News About These CompaniesAnalysts Set Invivyd, Inc. (NASDAQ:IVVD) Target Price at $4.89October 11 at 3:01 AM | americanbankingnews.comCantor Fitzgerald Estimates Invivyd FY2025 EarningsOctober 10, 2025 | marketbeat.comInvivyd (IVVD) Is Up 34.4% After FDA Clears Late-Stage COVID Antibody Program—What’s ChangedOctober 9, 2025 | finance.yahoo.comInvivyd (NASDAQ:IVVD) Receives "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comInvivyd (IVVD): Assessing Valuation After FDA Clears Phase 3 COVID-19 Antibody TrialOctober 8, 2025 | finance.yahoo.comCantor Fitzgerald Initiates Coverage on Invivyd (NASDAQ:IVVD)October 8, 2025 | americanbankingnews.comD. Boral Capital Maintains Invivyd (IVVD) Buy RecommendationOctober 7, 2025 | msn.comInvivyd announces IND clearance, alignment with FDA on VYD2311 programOctober 6, 2025 | msn.comCantor Fitzgerald Initiates Coverage of Invivyd (IVVD) with Overweight RecommendationOctober 6, 2025 | msn.comD. Boral Capital Increases Invivyd (NASDAQ:IVVD) Price Target to $2.00October 6, 2025 | marketbeat.com5 Analysts Have This To Say About InvivydOctober 6, 2025 | benzinga.comInvivyd, Inc. (NASDAQ:IVVD) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 6, 2025 | marketbeat.comInvivyd (NASDAQ:IVVD) Now Covered by Cantor FitzgeraldOctober 6, 2025 | marketbeat.comInvivyd’s VYD2311 Receives FDA Clearance for TrialsOctober 6, 2025 | tipranks.comInvivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVIDOctober 6, 2025 | globenewswire.comInvivyd files $350M mixed securities shelfOctober 2, 2025 | msn.comInvivyd (NASDAQ:IVVD) Stock Price Down 1.8% - Here's WhyOctober 1, 2025 | marketbeat.comInvivyd Appoints Paul B. Bolno, M.D. to Its Board of DirectorsSeptember 25, 2025 | markets.businessinsider.comInvivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody ApprovalSeptember 25, 2025 | finance.yahoo.comInvivyd Appoints New Director Amid Nasdaq ComplianceSeptember 25, 2025 | tipranks.comInvivyd, Inc. Appoints Dr. Paul B. Bolno to Board of DirectorsSeptember 24, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025The New Brain of Business: UiPath Is Creating an AI RevolutionBy Jeffrey Neal Johnson | October 2, 2025IPA, DSGN, IVVD, and AMRN Company DescriptionsAmarin NASDAQ:AMRN$19.32 +0.15 (+0.78%) Closing price 04:00 PM EasternExtended Trading$18.90 -0.42 (-2.17%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Design Therapeutics NASDAQ:DSGN$6.62 +0.13 (+2.00%) Closing price 04:00 PM EasternExtended Trading$6.62 0.00 (0.00%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.ImmunoPrecise Antibodies NASDAQ:IPAImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Invivyd NASDAQ:IVVD$1.63 -0.25 (-13.30%) Closing price 04:00 PM EasternExtended Trading$1.70 +0.08 (+4.60%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
